Interplay of Interleukin-1β and Curcumin on VEGF Expression in Breast Cancer Cells

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Vascular endothelial growth factor (VEGF) is crucial for tumor vascularization, responding to hypoxia and inflammation.
• The polyphenol curcumin may enhance anti-VEGF therapies by modulating inflammation-induced VEGF secretion.
• Breast cancer subtypes exhibit distinct molecular characteristics influencing treatment response.

Purpose of the Study:

• To investigate the interaction between curcumin and Interleukin-1β (IL-1β) on VEGF secretion in diverse breast cancer cell lines.
• To determine the role of specific signaling pathways, like ERK and p38-MAPK, in mediating these effects.
• To correlate in vitro findings with gene expression data from a breast cancer cohort.

Main Methods:

• Utilized Western blot and ELISA to quantify VEGF secretion and kinase phosphorylation.
• Employed inhibitor experiments to elucidate signaling pathway involvement.
• Analyzed gene expression data (HIF1A, IL-1β, VEGF) from the METABRIC study.
• Performed immunohistochemistry and survival analysis on a breast cancer cohort.

Main Results:

• Breast cancer cell lines (MCF-7, SK-BR-3, MDA-MB-231, UACC-3199) showed differential VEGF secretion and signaling responses to IL-1β and curcumin.
• IL-1β increased VEGF secretion only in MCF-7 cells; curcumin's effect varied, inhibiting in MDA-MB-231 but increasing in MCF-7 and UACC-3199 cells.
• Extracellular signal-regulated kinase (ERK) signaling was identified as a key mediator of VEGF secretion.

Conclusions:

• Breast cancer cell lines exhibit heterogeneous responses to IL-1β and curcumin, impacting VEGF secretion and signaling.
• Therapeutic strategies targeting VEGF, IL-1β, or using curcumin may have variable efficacy across breast cancer subtypes.
• These findings underscore the need for personalized treatment strategies in breast cancer therapy.